ANNX vs ANRO

Annexon, Inc. vs Alto Neuroscience, Inc. — Valuation Comparison 2026

ANNX

Biotechnology
Annexon, Inc.
Quality
4.2
out of 10
Value Trap
36
LOW
Price
$5.37
Last close
Models
7/13
Active
VS

ANRO

Biotechnology
Alto Neuroscience, Inc.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$20.22
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ANNX Fair ValueANNX Upside ANRO Fair ValueANRO Upside
Bayesian DCF Intrinsic $1.97 -63.4% $7.06 -65.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.09 -98.4% $1.90 -90.6%
Dynamic NAV Asset-Based $2.02 -62.4% $4.20 -79.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANNX vs ANRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANNX vs ANRO — Which Stock Is More Undervalued?

ANRO scores higher with a 4.7/10 quality rating vs ANNX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Annexon, Inc. (ANNX) and Alto Neuroscience, Inc. (ANRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANNX currently trades at $5.37 with a QOC of 4.2/10, while ANRO trades at $20.22 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).